HC Wainwright Has Pessimistic View of WINT FY2024 Earnings

Windtree Therapeutics, Inc. (NASDAQ:WINT) – Research analysts at HC Wainwright lowered their FY2024 earnings estimates for Windtree Therapeutics in a report released on Wednesday, December 4th. HC Wainwright analyst V. Bernardino now anticipates that the company will post earnings of ($5.66) per share for the year, down from their previous forecast of ($2.38). HC Wainwright has a “Neutral” rating and a $7.00 price target on the stock. The consensus estimate for Windtree Therapeutics’ current full-year earnings is ($5.66) per share. HC Wainwright also issued estimates for Windtree Therapeutics’ Q4 2024 earnings at ($0.92) EPS and FY2025 earnings at ($2.86) EPS.

Windtree Therapeutics Stock Performance

Shares of NASDAQ WINT opened at $0.37 on Friday. The company has a 50 day simple moving average of $0.76 and a two-hundred day simple moving average of $3.70. Windtree Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $16.74. The company has a market capitalization of $3.33 million, a price-to-earnings ratio of -0.02 and a beta of 0.54.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.